34
Participants
Start Date
April 30, 2006
Primary Completion Date
November 30, 2007
Study Completion Date
March 31, 2009
SU011248
Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Beth Israel Deaconess Medical Center
OTHER
Brigham and Women's Hospital
OTHER
Dana-Farber Cancer Institute
OTHER
Massachusetts General Hospital
OTHER